TFCP2L1 and urinary bladder cancer: CDK1 orchestrates a dual mechanism by directly engaging with the pivotal cancer stemness-related protein Sox2 to drive tumor initiation in melanoma, while simultaneously preserving tumor stemness characteristics and pluripotency through phosphorylating TFCP2L1 in human bladder cancer [10, 11].